Merck & Co. Inc. (NYSE:MRK) is one of the most promising stocks under $100. On October 6, Merck & Co. announced the initiation of three new Phase 2b trials for tulisokibart (MK-7240). Tulisokibart is an investigational humanized monoclonal antibody targeting tumor necrosis factor/TNF-like cytokine 1A/TL1A. The program expansion reflects Merck’s ongoing commitment to immune-mediated inflammatory diseases. The three new global Phase 2b trials are: MK-7240-12 for moderate to severe hidradenitis suppurativa/H ...